Satavaptan -: Vasopressin V2 antagonist treatment of hyponatremia treatment of cirrhotic ascites

被引：1
|
作者：
Revill, P. [1 ]
Serradell, N. [1 ]
Bolos, J. [1 ]
Bayes, M. [1 ]
机构：
[1] Prous Sci, Barcelona 08080, Spain
来源：
DRUGS OF THE FUTURE | 2007年 / 32卷 / 01期
关键词：
D O I：
10.1358/dof.2007.032.01.1068028
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Satavaptan is a potent and selective, orally available, nonpeptide vasopressin V-2 receptor antagonist. The agent blocks the effect of the antidiuretic hormone arginine-vasopressin (AVIP), promoting water excretion at the kidneys without the loss of sodium or potassium seen with traditional diuretics. Satavaptan has potential utility in the treatment of disorders with a water-retaining component and low plasma sodium levels, including the syndrome of inappropriate antidiuretic hormone secretion (SIADH) and ascites in liver cirrhosis. The agent has demonstrated utility in animal models and is undergoing late-stage clinical trials for these indications.
引用
收藏
页码：26 / 36
页数：11
相关论文
共 50 条
  • [1] Effects of satavaptan, a selective vasopressin V2 receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia:: A randomized trial
    Gines, Pere
    Wong, Florence
    Watson, Hugh
    Milutinovic, Slobodan
    del Arbol, Luis Ruiz
    Olteanu, Dan
    HEPATOLOGY, 2008, 48 (01) : 204 - 213
  • [2] LIXIVAPTAN Vasopressin V2 Receptor Antagonist Treatment of Heart Failure Treatment of Hyponatremia
    Daifallah, S.
    Zmily, H. D.
    Alqwasmi, A. H.
    Zayed, H.
    Ghali, J. K.
    DRUGS OF THE FUTURE, 2011, 36 (05) : 359 - 370
  • [3] Effects of a selective vasopressin V2 receptor antagonist, satavaptan (SR121463B), in patients with cirrhosis and ascites without hyponatremia
    Gines, Pere
    Wong, Florence
    Watson, Hugh R.
    Ruiz del Arbol, Luis R.
    Bilic, Ante
    Dobru, Daniela
    HEPATOLOGY, 2006, 44 (04) : 445A - 446A
  • [4] Effective short- and long-term treatment of dilutional hyponatremia with satavaptan, a highly selective vasopressin V2 receptor antagonist: the DILIPO study
    Krum, H.
    Verbalis, J. G.
    Mueller, M.
    Aronson, D.
    EUROPEAN HEART JOURNAL, 2008, 29 : 41 - 41
  • [5] Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis
    Wong, Florence
    Gines, Pere
    Watson, Hugh
    Horsmans, Yves
    Angeli, Paolo
    Gow, Paul
    Minini, Pascal
    Bernardi, Mauro
    JOURNAL OF HEPATOLOGY, 2010, 53 (02) : 283 - 290
  • [6] Conivaptan hydrochloride.: Treatment of heart failure, Treatment of hyponatremia, Vasopressin V1a/V2 antagonist.
    Norman, P
    Leeson, PA
    Rabasseda, X
    Castañer, J
    Castañer, RM
    DRUGS OF THE FUTURE, 2000, 25 (11) : 1121 - 1130
  • [7] Lixivaptan, a non-peptide vasopressin V2 receptor antagonist for the potential oral treatment of hyponatremia
    Ghali, Jalal K.
    Zmily, Hammam D.
    Farah, Jareer O.
    Daifallah, Suleiman
    IDRUGS, 2010, 13 (11) : 782 - 792
  • [8] A novel oral vasopressin V2 receptor antagonist for the treatment of acute decompensated heart failure and hyponatremia
    Jennings, Douglas L.
    Kalus, James S.
    FORMULARY, 2008, 43 (07) : 236 - +
  • [9] Effects of tolvaptan, an oral vasopressin V2 receptor antagonist, in hyponatremia
    Madias, Nicolaos E.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2007, 50 (02) : 184 - 187
  • [10] Effects of a selective vasopressin V2 receptor antagonist, satavaptan (SR121463B), on recurrence of ascites after large volume paracentesis
    Wong, Florence
    Gines, Pere
    Watson, Hugh
    Kujundzic, Milan
    Angeli, Paolo
    Horsmans, Yves
    HEPATOLOGY, 2006, 44 (04) : 256A - 256A
12345